Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 1;40(7):637-638.
doi: 10.1097/INF.0000000000003123.

Retapamulin Activity Against Pediatric Strains of Mupirocin-resistant Methicillin-resistant Staphylococcus aureus

Ami B Patel  1 , Jennifer Lighter  1   2 , Yi Fulmer  3 , Richard Copin  3 , Adam J Ratner  1   3 , Bo Shopsin  3   4
Affiliations

Retapamulin Activity Against Pediatric Strains of Mupirocin-resistant Methicillin-resistant Staphylococcus aureus

Ami B Patel et al. Pediatr Infect Dis J. .

Abstract

Retapamulin activity against 53 isolates obtained from a mupirocin-resistant community-acquired methicillin-resistant Staphylococcus aureus pediatric disease cluster was evaluated using broth microdilution. All strains were susceptible to retapamulin with minimum inhibitory concentrations ≤ 0.5 μg/mL. DNA sequence analysis of rplC and cfr identified one rplC strain variant that did not demonstrate reduced phenotypic susceptibility to retapamulin. These results demonstrate that retapamulin may be a useful alternative therapy for mupirocin-resistant community-acquired methicillin-resistant S. aureus, especially in disease clusters.

PubMed Disclaimer

Conflict of interest statement

J.L. and this work was supported by a grant from KiDS of New York University Foundation and from the generous donation of Judith and Irwin Kallman. B.S. is supported by the National Institutes of Health grants (R01 AI103268) and NIAID HHS (N272201400019C). A.P. and J.L. have received research grant funding from Aqua Pharmaceuticals. A.J.R. has acted as a consultant for Pfizer and served on an advisory board for Janssen, outside the scope of this work. B.S. has served on an advisory board for MicroGen diagnostics, outside the scope of this work. A donation from the Kallman family supported this work. B.S. is supported by the National Institutes of Health grants R01AI137336-01A1 and R01AI140754-01A1. The other authors have no conflicts of interest to disclose.

References

    1. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010;23(3):616–87. 10.1128/CMR.00081-09. - DOI - PMC - PubMed
    1. Ammerlaan HS, Harbarth S, Buiting AG, Crook DW, Fitzpatrick F, Hanberger H, et al. Secular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infection. Clin Infect Dis 2013;56(6):798–805. Epub 2012/12/12. 10.1093/cid/cis1006. - DOI - PubMed
    1. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355(7):666–74. Epub 2006/08/18. 10.1056/NEJMoa055356. - DOI - PubMed
    1. Popovich KJ, Weinstein RA, Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis 2008;46(6):787–94. Epub 2008/02/13. 10.1086/528716. - DOI - PubMed
    1. Seybold U, Kourbatova EV, Johnson JG, Halvosa SJ, Wang YF, King MD, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006;42(5):647–56. Epub 2006/02/01. 10.1086/499815. - DOI - PubMed

Publication types

MeSH terms